Shares of Aimmune Therapeutics (NASDAQ: AIMT), a company developing a peanut desensitization therapy, jumped 12% on Wednesday after an analyst shared the results of an informal survey. It looks like the company's lead candidate, Palforzia, could exceed expectations if the Food and Drug Administration follows advice from an independent advisory meeting in September.
Food allergies affect between 4% and 8% of children, and 1% to 2% of adults. The concept behind desensitization therapy isn't anything new, but Palforzia could become the first FDA-approved desensitization treatment with clinical trial data to back up its claims.
Image source: Getty Images.